The (FSR) is proud to celebrate a major milestone for the FSR Sarc Fighter Podcast, which has officially surpassed ...

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

The Foundation for Sarcoidosis Research (FSR) is proud to announce the three recipients of the 2025 FSR Early Career Fellowship Grant: William Lippitt, PhD, (University of Colorado Anschutz Medical ...

Thousands of people struggling with common respiratory conditions could be able to get extra financial support from the ...

Those battling severe asthma, upper respiratory tract diseases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis and ...

Thousands of people with common conditions that make breathing a struggle could be getting more support from the Government.

A successful claim for PIP or ADP is worth between £29.20 and £187.45 each week in additional financial support and as the benefit is paid every four weeks, this amounts to between £116.80 and £749.80 ...

Background Sarcoidosis is a rare lung disease in children. The aim of the present study was to provide update information on disease presentation and progression, patient management and prognosis ...

Research presented at ASCO 2025 highlighted advances in lung cancer as well as treatments that fell short of expectations.